Tenax Therapeutics Inc. advanced 3.8% in pre-market trading after the company presented additional data from its Phase 3 LEVEL trial of TNX-103, an oral formulation of levosimendan, at the European Society of Cardiology Congress 2026 in Munich on August 29.
The updated findings, delivered by Northwestern University’s Professor Sanjiv Shah, confirmed a favorable treatment effect in patients with lower baseline exercise capacity. The data also indicated that levosimendan’s benefit intensified with greater disease severity. These results carry implications for the drug’s regulatory pathway in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF), a condition currently lacking approved therapies.
Analysts at several major Wall Street firms initiated coverage with Buy-equivalent ratings, assigning price targets ranging from $35 to $40. The company’s cash position stood at approximately $118 million, providing funding through the second quarter of 2028.
The stock had been consolidating near multi-month lows since the initial topline data release on August 10. U.S. equity futures were trading marginally lower in pre-market, suggesting the advance was driven by the clinical news flow rather than broader market sentiment.
